Interestingly, EphB4 but not EphrinB2 has been identified as a predictive biomarker for therapy response in colorectal cancer patients receiving bevacizumab, with an increased EphB4 expression in non-responders [44]. The gene discussed is EFNB2; the disease is colorectal cancer.